Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, T-Cell

Explore clinical trials studying Lymphoma, T-Cell. Study availability and eligibility vary by location and protocol.

694 public trials 105 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, T-Cell trial results

Completed

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

NCT00050999

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • University of Texas, M.D. Anderson Cancer Center Houston, Texas, United States
  • Level 4 Department of Haematology Royal North Shore Hospital Saint Leonard's, New South Wales, Australia
  • Westmead Hospital, Department of Haematology Westmead, New South Wales, Australia
  • Mater Misericordiae Adult Hospital South Brisbane, Queensland, Australia
View all 35 locations
View Trial Details
Completed

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

NCT00051012

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • University of Texas, M.D. Anderson Cancer Center Houston, Texas, United States
  • Level 4 Department of Haematology Royal North Shore Hospital Saint Leonard's, New South Wales, Australia
  • Westmead Hospital, Department of Haematology Westmead, New South Wales, Australia
  • Mater Misericordiae Adult Hospital South Brisbane, Queensland, Australia
View all 34 locations
View Trial Details
Active, Not Recruiting

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

NCT05589896

Conditions
Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, +39 more
Locations
  • City of Hope Duarte, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Emory University - Winship Cancer Institute Atlanta, Georgia, United States
  • Henry Ford Cancer Institute Detroit, Michigan, United States
View Trial Details
Active, Not Recruiting

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

NCT04703192

Conditions
Adult T Cell Leukemia/Lymphoma, Hematologic Diseases, Hemic and Lymphatic Diseases, +15 more
Locations
  • City Of Hope National Medical Center Duarte, California, United States
  • Stanford University Medical Center - Cancer Clinical Trials Office - ONCOLOGY Palo Alto, California, United States
  • University of California San Francisco San Francisco, California, United States
  • University Of Colorado Cancer Center Aurora, Colorado, United States
View all 60 locations
View Trial Details
Active, Not Recruiting

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

NCT04652960

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +13 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida, United States
View all 17 locations
View Trial Details

Related conditions